Showing results (111-120 of 682) with videos related to
Sort By:
Pageof 69
Leukemia & Lymphoma|February 15, 2014
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyureaMatjaz Sever, Kate J Newberry, Srdan VerstovsekAnnals of Hematology|March 2, 2017
Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractionsPaolo Strati, Prithviraj Bose, Lindsey Lyle, et al.Leukemia & Lymphoma|November 15, 2021
Novel strategies for challenging scenarios encountered in managing myelofibrosisPrithviraj Bose, Ruben A MesaCancer Cell|March 14, 2018
ORY-1001: Overcoming the Differentiation Block in AMLPrithviraj Bose, Marina Y KonoplevaExpert Opinion on Pharmacotherapy|July 27, 2024
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literatureAnthony M Hunter, Prithviraj BoseClinical Lymphoma, Myeloma & Leukemia|August 21, 2024
SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic MastocytosisHelen T Chifotides, Prithviraj BoseFuture Oncology (London, England)|March 12, 2015
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosisCecilia Arana Yi, Constantine S Tam, Srdan VerstovsekExpert Opinion on Investigational Drugs|June 4, 2011
A potential role of ruxolitinib in leukemiaKiran Naqvi, Srdan Verstovsek, Hagop Kantarjian, et al.Blood Reviews|January 12, 2015
Mechanisms of thrombogenesis in polycythemia veraMichael H Kroll, Laura C Michaelis, Srdan VerstovsekInternational Journal of Hematology|August 29, 2016
Ruxolitinib dose management as a key to long-term treatment successRuben A Mesa, Rami S Komrokji, Srdan VerstovsekPageof 69